Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APTEVO THERAPEUTICS INC.

(APVO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
7.3(c) 6.48(c) 17.03(c) 11.95(c) 13.07(c) Last
435 909 629 484 164 120 486 24 745 919 7 609 542 Volume
-9.88% -11.23% +162.81% -29.83% +9.37% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 12,0 M - -
Net income 2021 -28,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,13x
Yield 2021 -
Sales 2022 15,9 M - -
Net income 2022 -28,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,42x
Yield 2022 -
Capitalization 64,0 M 64,0 M -
Capi. / Sales 2021 5,32x
Capi. / Sales 2022 4,03x
Nbr of Employees 58
Free-Float 94,7%
More Financials
Company
Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The Company has two modular protein platforms of technology: ADAPTIR and ADAPTIR-FLEX. It is designed to generate monospecific, bispecific and multispecific antibody candidates that are capable for the human... 
More about the company
Ratings of Aptevo Therapeutics Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about APTEVO THERAPEUTICS INC.
11/24Top Premarket Decliners
MT
11/23Aptevo Reports First Complete Remission in Trial of Acute Myeloid Leukemia Cell Therapy..
MT
11/23APTEVO THERAPEUTICS : Reports First Complete Remission, Providing Clinical Update for its ..
PU
11/23APTEVO THERAPEUTICS : Reports First Complete Remission, Providing Clinical Update for Its ..
PU
11/23APTEVO THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/23Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial E..
CI
11/22INSIDER SELL : Aptevo Therapeutics
MT
11/15Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
AQ
11/15Roth Capital Adjusts Aptevo Therapeutics' Price Target to $36 From $50, Reiterates Buy ..
MT
11/15APTEVO THERAPEUTICS : Announces the Presentation of Two Abstracts at the Upcoming American..
PU
11/12Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
PU
11/12APTEVO THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS WITH BUSINESS HIGHLIGHTS - ..
PU
11/12APTEVO THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/12Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/11Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-..
PU
More news
News in other languages on APTEVO THERAPEUTICS INC.
11/23Aptevo annonce la première rémission complète dans le cadre d'un essai de thérapie cell..
11/22VENTE PAR DES INITIÉS : Aptevo Therapeutics
More news
Analyst Recommendations on APTEVO THERAPEUTICS INC.
More recommendations
Chart APTEVO THERAPEUTICS INC.
Duration : Period :
Aptevo Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APTEVO THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 13,07 $
Average target price 52,50 $
Spread / Average Target 302%
EPS Revisions
Managers and Directors
Marvin L. White President, Chief Executive Officer & Director
Jeffrey G. Lamothe Chief Financial Officer, Treasurer & Senior VP
Fuad El Hibri Chairman
Scott C. Stromatt Chief Medical Officer & SVP-Clinical Development
Daniel J. Abdun-Nabi Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APTEVO THERAPEUTICS INC.-64.34%64
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678